Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization

Sarah R. Pickens, Nathan D. Chamberlain, Michael V. Volin, Mark Gonzalez, Richard M. Pope, Arthur M. Mandelin, Jay K. Kolls, Shiva Shahrara*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


IL-17-induced joint inflammation is associated with increased angiogenesis. However, the mechanism by which IL-17 mediates angiogenesis is undefined. Therefore, the pathologic role of CXCL1 and CXCL5 was investigated in arthritis mediated by local expression of IL-17, employing a neutralizing antibody to each chemokine. Next, endothelial chemotaxis was utilized to examine whether endothelial migration was differentially mediated by CXCL1 and CXCL5. Our results demonstrate that IL-17-mediated disease activity was not affected by anti-CXCL1 treatment alone. In contrast, mice receiving anti-CXCL5 demonstrated significantly reduced clinical signs of arthritis, compared to the mice treated with IgG control. Consistently, while inflammation, synovial lining thickness, bone erosion and vascularization were markedly reduced in both the anti-CXCL5 and combination anti-CXCL1 and 5 treatment groups, mice receiving anti-CXCL1 antibody had clinical scores similar to the control group. In contrast to joint FGF2 and VEGF levels, TNF-α was significantly reduced in mice receiving anti-CXCL5 or combination of anti-CXCL1 and 5 therapies compared to the control group. We found that, like IL-17, CXCL1-induced endothelial migration is mediated through activation of PI3K. In contrast, activation of NF-κB pathway was essential for endothelial chemotaxis induced by CXCL5. Although CXCL1 and CXCL5 can differentially mediate endothelial trafficking, blockade of CXCR2 can inhibit endothelial chemotaxis mediated by either of these chemokines. These results suggest that blockade of CXCL5 can modulate IL-17-induced inflammation in part by reducing joint blood vessel formation through a non-overlapping IL-17 mechanism.

Original languageEnglish (US)
Pages (from-to)443-455
Number of pages13
Issue number4
StatePublished - Dec 2011


  • Angiogenesis
  • CXCL1
  • CXCL5
  • IL-17-induced arthritis

ASJC Scopus subject areas

  • Physiology
  • Clinical Biochemistry
  • Cancer Research


Dive into the research topics of 'Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by decreasing joint vascularization'. Together they form a unique fingerprint.

Cite this